Therapeutic Response to Octreotide in Patients with Refractory CPT-11 Induced Diarrhea
- 1 November 2001
- journal article
- case report
- Published by Springer Nature in Investigational New Drugs
- Vol. 19 (4) , 341-343
- https://doi.org/10.1023/a:1010678214152
Abstract
Purpose. Severe diarrhea can represent adose-limiting toxicity with the use ofCPT-11. Conventional therapy isineffective in some patients and is alsolimited by patient compliance. We reportour...Keywords
This publication has 10 references indexed in Scilit:
- Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.Journal of Clinical Oncology, 1998
- Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.Journal of Clinical Oncology, 1996
- Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.Journal of Clinical Oncology, 1995
- Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea.Journal of Clinical Oncology, 1995
- Control of Chemotherapy-Induced Diarrhea with OctreotideOncology, 1994
- Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinomaCancer, 1993
- Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapyAnti-Cancer Drugs, 1993
- Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial.Journal of Clinical Oncology, 1993
- A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.Journal of Clinical Oncology, 1987